List of references for the Education Section

  1. Weycker D, Edelsberg J, Oster G, Tine G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12:205 – 209.
  2. O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635–42.
  3. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432–9.
  4. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006;100:2183–9.
  5. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, Catalan Serra P, Agramunt Lerma M, Ballestin Vicente J, Perpina-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest 2011; 140(5):1130-7.
  6. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010;86:493–501.
  7. Smith MP. Non-cystic fibrosis bronchiectasis. J R Coll Physicians Edinb 2011;41:132–9.
  8. Goemminne PC, Vandooren J, Moelants EA et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology 2013;Nov 29 epub ahead of print
  9. King PT, Holdsworth SR, Farmer M, Freezer NJ, Holmes PW. Chest pain and exacerbations of bronchiectasis. Int J Gen Med 2012;5:1019-24.
  10. King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. Intern Med J 2006;36:729–37.
  11. Guilemany JM, Marino-Sanchez FS, Angrill J et al. The importance of smell in patients with bronchiectasis. Respir Med 2011; 105(1):44-9.
  12. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65:suppl 1:i1-58.
  13. Devaraj A, Well AU, Meister MG, Loebinger MR, Wilson R, Hansell DM. Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. AJR Am J Roentgenol 2011;196(6):1300-4.
  14. Joish VN, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013;11(3):299-304.
  15. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132(5):1565-72.
  16. Chalmers JD, Goeminne P, Aliberti S et al. Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. Am J Respir Crit Care Med in press.
  17. Goeminne PC, Scheers H, Decraene A et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13:21.
  18. Hill AT, Welham S, Reid K, Bucknall CE. British Thoracic Society National Bronchiectasis Audit 2010 and 2011. Thorax 2012;67:928-930.
  19. Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156:536–41.
  20. Chalmers JD, McHugh BJ, Doherty CJ, Govan JR, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in non-CF bronchiectasis. Thorax 2012; 68(1):39-47.
  21. Chan SL, Chan-Yeung MM, Ooi GC, Lam CL, Cheung TF, Lam WK, et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. Chest 2002;122:2030–7.
  22. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:1086–92.
  23. Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George’s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156:536–41.
  24. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128:739–45.
  25. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–54.
  26. Raghu G, King TE, Behr J, Brown KK, du Bois RM, Leconte I, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010;35:118–23.
  27. Bahous J, Cartier A, Pineau L, Bernard C, Ghezzo H, Martin RR, et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir n.d.;20:375–80.
  28. Pande JN, Jain BP, Gupta RG, Guleria JS. Pulmonary ventilation and gas exchange in bronchiectasis. Thorax 1971;26:727–33.
  29. Roberts HR, Wells AU, Milne DG, Rubens MB, Kolbe J, Cole PJ, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000;55:198–204.
  30. Hill SL, Stockley RA. Effect of short and long term antibiotic response on lung function in bronchiectasis. Thorax 1986;41:798–800.
  31. Hassan JA, Saadiah S, Roslan H, Zainudin B. Bronchodilator response to inhaled beta-2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology 1999;4:423–6.
  32. Pang J, Chan HS, Sung JY. Prevalence of asthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study. Thorax 1989;44:948–51.
  33. McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013;188:647–56.
  34. Kang EY, Miller RR, Müller NL. Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens. Radiology 1995;195:649–54.
  35. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995;165:261–7.
  36. McGuinness G, Naidich DP. CT of airways disease and bronchiectasis. Radiol Clin North Am 2002;40:1–19.
  37. Chalmers JD, Smith MP, McHugh B, Doherty C, Govan JRW, Hill AT. Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med. 2012; 186(7):657-65.
  38. Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991;179:783–8.
  39. Ringshausen FC, de Roux A, Pletz MW et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011L a population-based study of disease burden and trends. Plos One 2013;8(8):e71109.
  40. Anwar GA, McDonnell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med 2013;107:1001–7.
  41. Li AM, Sonnappa S, Lex C, Wong E, Zacharasiewicz A, Bush A, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005;26:8–14.
  42. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013;55:27–34.
  43. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007;101:1163–70.
  44. King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 2009;4:411–9.
  45. Wood P, Peckham D. Investigating recurrent respiratory tract infections in primary care. BMJ 2009;339:b4118.
  46. Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006;27(2):185-91.
  47. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756–62.
  48. Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis. Model of bronchopulmonary disease with defined serologic, radiologic, pathologic and clinical findings from asthma to fatal destructive lung disease. Chest 1987;91:165S–171S.
  49. Gifford A, Chalmers JD. The role of neutrophils in cystic fibrosis. Current Opinion in Haematology 2014; 21(1):16-22.
  50. Wickremasinghe M, Ozerovitch LJ, Davies G et al. Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax  2005;60:1045-1051.
  51. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68:731–7.
  52. Tunney MM, Einarsson GG, Wei L et al. Lung microbiota and bacterial abundance in patietns with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187(10);118-26.
  53. Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6–15.
  54. Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57:15–9.
  55. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995; 108(4):955-61.
  56. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis:the influence of Pseudomonas aeruginosa.  Eur Respir J 1996;9(8):1601-4.
  57. Cabello H, Torres A, celis R et al. Bacterial colonization of distal airways in healthy subjects and chronic lung diease: a bronchoscopic study. Eur Respir J 1997;10(5):1137-44.
  58. Wilson CB, Jones PW, O’Leary CJ et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10(8):1754-60.
  59. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277–84.
  60. Angrill J, Agusti C, De Celis R et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164(9):1628-32.
  61. Palwatwichai A, Chaoprasong C, Vattanathum A, Wongsa A, Jatakanon A. Clinical laboratory findings and microbioloic characterization of bronchiectasis in Thai patients. Respirology 2002; 7(1):63-6.
  62. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003; 14(8):488-492.
  63. Tsang KW, Tan KC, Ho PL et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005;60(3);239-43.
  64. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101(8):1633-8.
  65. O’Connell M, Prevots DR, Olivier KN et al. The bronchiectasis research registry: clinical, microbiologic, and treatment characteristics. Am J Respir Crit Care Med 2010; A3172.
  66. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380(9842):660-7.
  67. Chalmers JD, McHugh BJ, Doherty CJ, Govan JRW, Kilpatrick DC, Hill AT. Mannose binding lectin deficiency and disease severity in non-CF bronchiectasis: a prospective study. Lancet Respiratory Medicine; 1(3):175-274.
  68. Watt AP, Brown V, Courtney J, Kelly M, Garske L, Elborn JS, Ennis M. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004; 59(3):231-6.
  69. Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill AT. Safety and Efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(2):416-23
  70. Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2011; 37(4):858-64
  71. Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184 (4):459-66.
  72. Martinez Garcia MA, de Gracia J, Vendrell Relat M et al. Multidimensional approach to non-cystic fibrosis bronchiectasis; the FACED score. Eur Respir J 2014;43(5):1357-67.
  73. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34(4):843-9.
  74. Finklea JD, Khan G, Thomas S, Song J, Myers D, Arroliga AC. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med 2010;104:816–21.
  75. Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis 2007;4:23–30.
  76. Nicolini A, Cardini F, Landucci N, Lanata S, Ferrari-Bravo M, Barlascini C. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med 2013;13:21.
  77. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006:CD002996.
  78. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99:27–31.
  79. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159:1843–8.
  80. Bilton D, Daviskas E, Anderson SD et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25.
  81. O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329–34.
  82. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EHJ, Koppers RJH, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309:1251–9.
  83. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309:1260–7.
  84. Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20);1881-90.
  85. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram AR, Taylor JK, Singanayagam A, Hill AT, Chalmers JD. Cardiovascular events following Clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346;f1235.
  86. Altenburg J, de Graaff CS, Van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics. Respiration 2011;81(1):75-87.
  87. Murray MP, Govan JRW, Docherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening A, Haslett C, Hill AT. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183(4):491-9.
  88. Serisier DJ, Bilton D, De Soyza A et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68(9):812-7.
  89. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481–5.
  90. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009:CD000996.
  91. Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 2010; 103(6):379-85.
  92. Stockley R, De Soyza A, Gunawardena K et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013; 107(4):524-33.
  93. Ong HK, Lee AL, Hill CJ et al. Effects of pulmonary rehabilitation in bronchiectasis: a retrospective study. Chron Respir Dis 2011;8(1):21-3